AAAAAA

   
Results: 1-25 | 26-46
Results: 1-25/46
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management ofupper tract transitional cell carcinoma in individuals with a normal contralateral kidney
Authors: Elliott, DS Segura, JW Lightner, D Patterson, DE Blute, ML
Citation: Ds. Elliott et al., Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management ofupper tract transitional cell carcinoma in individuals with a normal contralateral kidney, UROLOGY, 58(2), 2001, pp. 174-178
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy
Authors: Roberts, WW Bergstralh, EJ Blute, ML Slezak, JM Carducci, M Han, M Epstein, JI Eisenberger, MA Walsh, PC Partin, AW
Citation: Ww. Roberts et al., Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy, UROLOGY, 57(6), 2001, pp. 1033-1037
Chemoprevention for prostatic carcinoma: The role of flutamide in patientswith prostatic intraepithelial neoplasia
Authors: Alberts, SR Blute, ML
Citation: Sr. Alberts et Ml. Blute, Chemoprevention for prostatic carcinoma: The role of flutamide in patientswith prostatic intraepithelial neoplasia, UROLOGY, 57(4A), 2001, pp. 188-190
PSA doubling time as a predictor of clinical progression after biochemicalfailure following radical prostatectomy for prostate cancer
Authors: Roberts, SG Blute, ML Bergstralh, EJ Slezak, JM Zincke, H
Citation: Sg. Roberts et al., PSA doubling time as a predictor of clinical progression after biochemicalfailure following radical prostatectomy for prostate cancer, MAYO CLIN P, 76(6), 2001, pp. 576-581
Medical management of overactive bladder
Authors: Elliott, DS Lightner, DJ Blute, ML
Citation: Ds. Elliott et al., Medical management of overactive bladder, MAYO CLIN P, 76(4), 2001, pp. 353-355
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer
Authors: Zincke, H Lau, W Bergstralh, E Blute, ML
Citation: H. Zincke et al., Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer, J UROL, 166(6), 2001, pp. 2208-2215
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: Differences in outcome between primary Gleason grades 3 and 4
Authors: Lau, WK Blute, ML Bostwick, DG Weaver, AL Sebo, TJ Zincke, H
Citation: Wk. Lau et al., Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: Differences in outcome between primary Gleason grades 3 and 4, J UROL, 166(5), 2001, pp. 1692-1697
Stage pT1 conventional (clear cell) renal cell carcinoma: Pathological features associated with cancer specific survival
Authors: Cheville, JC Blute, ML Zincke, H Lohse, CM Weaver, AL
Citation: Jc. Cheville et al., Stage pT1 conventional (clear cell) renal cell carcinoma: Pathological features associated with cancer specific survival, J UROL, 166(2), 2001, pp. 453-456
Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?
Authors: Amling, CL Bergstralh, EJ Blute, ML Slezak, JM Zincke, H
Citation: Cl. Amling et al., Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?, J UROL, 165(4), 2001, pp. 1146-1151
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy
Authors: Blute, ML Bergstralh, EJ Iocca, A Scherer, B Zincke, H
Citation: Ml. Blute et al., Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy, J UROL, 165(1), 2001, pp. 119-125
Role of HPC2/ELAC2 in hereditary prostate cancer
Authors: Wang, L McDonnell, SK Elkins, DA Slager, SL Christensen, E Marks, AF Cunningham, JM Peterson, BJ Jacobsen, SJ Cerhan, JR Blute, ML Schaid, DJ Thibodeau, SN
Citation: L. Wang et al., Role of HPC2/ELAC2 in hereditary prostate cancer, CANCER RES, 61(17), 2001, pp. 6494-6499
Pathologic staging of renal cell carcinoma - Significance of tumor classification with the 1997 TNM staging system
Authors: Gettman, MT Blute, ML Spotts, B Bryant, SC Zincke, H
Citation: Mt. Gettman et al., Pathologic staging of renal cell carcinoma - Significance of tumor classification with the 1997 TNM staging system, CANCER, 91(2), 2001, pp. 354-361
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management - A retrospective analysis
Authors: Barry, MJ Albertsen, PC Bagshaw, MA Blute, ML Cox, R Middleton, RG Gleason, DF Zincke, H Bergstralh, EJ Jacobsen, SJ
Citation: Mj. Barry et al., Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management - A retrospective analysis, CANCER, 91(12), 2001, pp. 2302-2314
Predicting prostate carcinoma volume and stage at radical prostatectomy byassessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen - A report of 454 cases
Authors: Sebo, TJ Cheville, JC Riehle, DL Lohse, CM Pankratz, VS Myers, RP Blute, ML Zincke, H
Citation: Tj. Sebo et al., Predicting prostate carcinoma volume and stage at radical prostatectomy byassessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen - A report of 454 cases, CANCER, 91(11), 2001, pp. 2196-2204
Risk of prostate carcinoma death in patients with lymph node metastasis
Authors: Cheng, L Zincke, H Blute, ML Bergstralh, EJ Scherer, B Bostwick, DG
Citation: L. Cheng et al., Risk of prostate carcinoma death in patients with lymph node metastasis, CANCER, 91(1), 2001, pp. 66-73
Risk of prostate carcinoma death in patients with lymph node metastasis
Authors: Cheng, L Zincke, H Blute, ML Bergstralh, EJ Scherer, D Bostwick, DG
Citation: L. Cheng et al., Risk of prostate carcinoma death in patients with lymph node metastasis, CANC CYTOP, 91(1), 2001, pp. 66-73
The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy
Authors: Cheng, L Lloyd, RV Weaver, AL Pisansky, TM Cheville, JC Ramnani, DM Leibovich, BC Blute, ML Zincke, H Bostwick, DG
Citation: L. Cheng et al., The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy, CLIN CANC R, 6(5), 2000, pp. 1896-1899
Proximity of prostate cancer to the urethra: Implications for minimally invasive ablative therapies
Authors: Leibovich, BC Blute, ML Bostwick, DG Wilson, TM Pisansky, TM Davis, BJ Ramnani, DM Cheng, L Sebo, TJ Zincke, H
Citation: Bc. Leibovich et al., Proximity of prostate cancer to the urethra: Implications for minimally invasive ablative therapies, UROLOGY, 56(5), 2000, pp. 726-729
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney
Authors: Lau, WKO Blute, ML Weaver, AL Torres, VE Zincke, H
Citation: Wko. Lau et al., Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney, MAYO CLIN P, 75(12), 2000, pp. 1236-1242
Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease
Authors: Blute, ML Amling, CL Bryant, SC Zincke, H
Citation: Ml. Blute et al., Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease, MAYO CLIN P, 75(10), 2000, pp. 1020-1026
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer
Authors: Blute, ML Bergstralh, EJ Partin, AW Walsh, PC Kattan, MW Scardino, PT Montie, JE Pearson, JD Slezak, JM Zincke, H
Citation: Ml. Blute et al., Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer, J UROL, 164(5), 2000, pp. 1591-1595
1999 American Urological Association Gallup Survey: Changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care
Authors: O'Leary, MP Gee, WF Holtgrewe, HL Blute, ML Cooper, TP Miles, BJ Nellans, RE Thomas, R Painter, MR Meyer, JJ Naslund, MJ Gormley, EA Blizzard, R Fenninger, RB
Citation: Mp. O'Leary et al., 1999 American Urological Association Gallup Survey: Changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care, J UROL, 164(4), 2000, pp. 1311-1316
Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus
Authors: Karnes, RJ Gettman, MT Anderson, PM Lager, DJ Blute, ML
Citation: Rj. Karnes et al., Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus, J UROL, 164(3), 2000, pp. 772-772
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy
Authors: Itano, NB Blute, ML Spotts, B Zincke, H
Citation: Nb. Itano et al., Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy, J UROL, 164(2), 2000, pp. 322-325
Long-term hazard of progression after radical prostatectomy for clinicallylocalized prostate cancer: Continued rise of biochemical failure after 5 years
Authors: Amling, CL Blute, ML Bergstralh, EJ Seay, TM Slezak, J Zincke, H
Citation: Cl. Amling et al., Long-term hazard of progression after radical prostatectomy for clinicallylocalized prostate cancer: Continued rise of biochemical failure after 5 years, J UROL, 164(1), 2000, pp. 101-105
Risultati: 1-25 | 26-46